J. Lecomte

发表

Prognostic factors for patients with small cell lung carcinoma

V. Ninane, M. Paesmans, J. Sculier, 2000, Cancer.

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

J. Lafitte, V. Ninane, M. Paesmans, 2007, British Journal of Cancer.

A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.

P. van Houtte, M. Paesmans, T. Berghmans, 2009, Lung cancer.

A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.

J. Lafitte, P. van Houtte, M. Paesmans, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

European Lung Cancer Working Party Clinical Practice Guidelines Non-small Cell Lung Cancer: II. Unresectable Non-metastatic Stages

J. Lafitte, V. Ninane, C. Mascaux, 2006 .

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: IV. Limited disease.

J. Lafitte, P. Houtte, M. Paesmans, 2007 .

European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: V. Extensive diseases.

J. Lafitte, P. Houtte, P. Wackenier, 2007 .

A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer.

J. Lafitte, V. Ninane, P. van Houtte, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

J. Lafitte, V. Ninane, M. Paesmans, 2001, British Journal of Cancer.

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

J. Lafitte, M. Paesmans, T. Berghmans, 2017, Front. Oncol..

Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.

M. Paesmans, J. Sculier, J. Klastersky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original article: A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

J. Lafitte, V. Ninane, M. Paesmans, 2000 .

Chemotherapy improves low performance status lung cancer patients

J. Lafitte, V. Ninane, M. Paesmans, 2007, European Respiratory Journal.

A phase III randomised trial comparing sequential to standard chemotherapy in advanced non-small cell lung cancer (NSCLC).

J. Lafitte, M. Paesmans, T. Berghmans, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An ELCWP phase III trial comparing ifosfamide and cisplatin regimens in advanced NSCLC.

J. Lafitte, M. Paesmans, T. Berghmans, 2013, Anticancer research.

Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer

M. Paesmans, J. Sculier, J. Body, 1990, Cancer.

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

J. Lafitte, P. V. Van Schil, P. van Houtte, 2011, European Respiratory Journal.

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, M. Paesmans, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.

J. Sculier, J. Klastersky, J. Lecomte, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).

M. Paesmans, J. Sculier, J. Klastersky, 1996, Lung cancer.

A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party.

J. Sculier, J. Klastersky, J. Lecomte, 1990, Seminars in oncology.

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party.

J. Sculier, J. Klastersky, J. Lecomte, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Validation and comparison of several published prognostic systems for patients with small cell lung cancer

J. Lafitte, P. van Houtte, M. Paesmans, 2011, European Respiratory Journal.

A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer

M. Paesmans, J. Sculier, J. Klastersky, 1990 .

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.

T. Berghmans, J. Sculier, G. Koumakis, 2004, Lung cancer.

European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages

J. Lafitte, V. Ninane, T. Berghmans, 2006 .

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, M. Paesmans, 1999, European journal of cancer.

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.

J. Lafitte, M. Paesmans, T. Berghmans, 2005, Lung cancer.